EPCAM and hepatocellular carcinoma: To evaluate the sensitivity of HCC cells with distinct EpCAM/CD90 expression status to sorafenib, we utilized two HCC clones (Milano hcc-1 and Milano hcc-2) derived from a previously established single HCC tissue (intratumor heterogeneity)13.